Ilginatinib (NS-018)
≥98%
- Product Code: 108586
CAS:
1239358-86-1
| Molecular Weight: | 389.43 g./mol | Molecular Formula: | C₂₁H₂₀FN₇ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Ilginatinib is primarily used in the treatment of myelofibrosis, a rare bone marrow disorder. It works by inhibiting JAK2, a protein involved in the signaling pathways that promote the growth of abnormal blood cells. This helps reduce symptoms such as enlarged spleen, fatigue, and bone pain. Additionally, it is being investigated for its potential in treating other hematologic malignancies due to its targeted action on JAK-STAT signaling pathways. Its ability to selectively target specific pathways makes it a promising option for patients with limited treatment alternatives.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿40,176.00 |
+
-
|
Ilginatinib (NS-018)
Ilginatinib is primarily used in the treatment of myelofibrosis, a rare bone marrow disorder. It works by inhibiting JAK2, a protein involved in the signaling pathways that promote the growth of abnormal blood cells. This helps reduce symptoms such as enlarged spleen, fatigue, and bone pain. Additionally, it is being investigated for its potential in treating other hematologic malignancies due to its targeted action on JAK-STAT signaling pathways. Its ability to selectively target specific pathways makes it a promising option for patients with limited treatment alternatives.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :